Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of TAR-210 versus investigator's choice intravesical chemotherapy in FGFR-altered high-risk non-muscle-invasive bladder cancer after BCG
CTR20253493Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Erda-iDRS in bladder cancer, sponsored by Janssen Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
Erda-iDRS
03
Conditions
bladder cancer
Beyond the preview
Go deeper on CTR20253493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253493.